Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
List view / Grid view
News
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients
2 June 2014 | By AstraZeneca
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute...
New detailed Phase 3 data show Amgen’s novel investigational cholesterol-lowering medication evolocumab significantly reduced LDL Cholesterol
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
Avacta Analytical sponsors 5th Annual Protein Formulation Development and Drug Delivery Forum
2 June 2014 | By kdm communications
Avacta Analytical is pleased to announce its sponsorship of this year’s Protein Formulation Development and Drug Delivery Forum in Barcelona, Spain...
CHMP adopts positive opinion for plegridytm (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
30 May 2014 | By Biogen Idec
Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the marketing authorisation of PLEGRIDY...
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at medical congresses
30 May 2014 | By Biogen Idec
Biogen Idec announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis therapies are being featured during two neurology conferences...
Dr. Morris J. Birnbaum joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research
30 May 2014 | By Pfizer
Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research...
Genzyme’s Lemtrada resubmission accepted for review by FDA
30 May 2014 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada...
European Medicines Agency welcomes publication of the Clinical Trials Regulation
29 May 2014 | By The European Medicines Agency
The European Medicines Agency welcomes the publication of the Clinical Trials Regulation in the Official Journal of the European Union...
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation
29 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa®...
Lundbeck to present new Brintellix® data at the Annual Society of Clinical Psychopharmacology (ASCP) Meeting
29 May 2014 | By H. Lundbeck A/S
Data highlights safety and efficacy profile of Brintellix, including difficult to treat patients and special patient populations...
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
28 May 2014 | By Sanofi
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil)...
Bristol-Myers Squibb and Incyte enter clinical collaboration agreement to evaluate combination regimen of two novel immunotherapies
28 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...
Pfizer brings frequent heartburn relief over-the-counter with new Nexium® 24HR
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
